


Amendments to the Claims:

This listing of claims replaces all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound of Formula I



or a pharmaceutically acceptable salt or hydrate thereof, wherein:

Ar is phenyl or naphthyl;

A is selected from: ~~-CO₂H, 1*H* tetrazol-5-yl, PO₃H₂, PO₂H₂, SO₃H, and -PO(R⁵)OH~~, wherein R⁵ is selected from the group consisting of: C₁₋₄alkyl, hydroxyC₁₋₄alkyl, phenyl, C(O)C₁₋₃alkoxy and CH(OH)phenyl, said phenyl and phenyl portion of CH(OH)phenyl optionally substituted with 1-3 substituents independently selected from the group consisting of: hydroxyl, halo, CO₂H, C₁₋₄alkyl, S(O)_kC₁₋₃alkyl, wherein k is 0, 1 or 2, C₁₋₃alkoxy, C₃₋₆cycloalkoxy, aryl and aralkoxy, the alkyl portions of said C₁₋₄alkyl, S(O)_kC₁₋₃alkyl, C₁₋₃alkoxy and C₃₋₆cycloalkoxy optionally substituted with 1-3 halo groups;

n is 2, 3 or 4;

each R¹ and R² is each independently selected from the group consisting of: hydrogen, halo, hydroxy, -CO₂H, C₁₋₆alkyl and phenyl, said C₁₋₆alkyl and phenyl optionally substituted with 1-3 halo groups;

R^3 is selected from the group consisting of: hydrogen and C_{1-4} alkyl, optionally substituted with 1-3 hydroxy or halo groups;

each R^4 is independently selected from the group consisting of: hydroxy, halo, $-CO_2H$, C_{1-4} alkyl, $-S(O)_kC_{1-3}$ alkyl, wherein k is 0, 1 or 2, C_{1-3} alkoxy, C_{3-6} cycloalkoxy, aryl and aralkoxy, the alkyl portions of said C_{1-4} alkyl, $-S(O)_kC_{1-3}$ alkyl, C_{1-3} alkoxy and C_{3-6} cycloalkoxy optionally substituted with 1-3 halo groups;


C is selected from the group consisting of:

- (1) ~~C_{1-8} alkyl, C_{1-8} alkoxy, $(C=O)C_{1-6}$ alkyl or $CHOH-C_{1-6}$ alkyl, said C_{1-8} alkyl, C_{1-8} alkoxy, $(C=O)C_{1-6}$ alkyl and $CHOH-C_{1-6}$ alkyl optionally substituted with phenyl, and~~
- (2) ~~phenyl or HET, wherein HET is thienyl each optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, phenyl, C_{1-4} alkyl and C_{1-4} alkoxy, said C_{1-4} alkyl and C_{1-4} alkoxy groups optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxyl, and said phenyl optionally substituted with 1 to 5 groups independently selected from the group consisting of: halo and C_{1-4} alkyl, optionally substituted with 1-3 halo groups,~~

or C is not present;

when C is not present then B is selected from the group consisting of: phenyl, C_{5-16} alkyl, C_{5-16} alkenyl, C_{5-16} alkynyl, $CHOH-C_{4-15}$ alkyl, $CHOH-C_{4-15}$ alkenyl, $CHOH-C_{4-15}$ alkynyl, C_{4-15} alkoxy, $O-C_{4-15}$ alkenyl, $O-C_{4-15}$ alkynyl, C_{4-15} alkylthio, $S-C_{4-15}$ alkenyl, $S-C_{4-15}$ alkynyl, CH_2-C_{3-14} alkoxy, CH_2-O-C_{3-14} alkenyl, CH_2-O-C_{3-14} alkynyl, $(C=O)-C_{4-15}$ alkyl, $(C=O)-C_{4-15}$ alkenyl, $(C=O)-C_{4-15}$ alkynyl, $(C=O)-O-C_{3-14}$ alkyl, $(C=O)-O-C_{3-14}$ alkenyl, $(C=O)-O-C_{3-14}$ alkynyl, $(C=O)-N(R^6)(R^7)-C_{3-14}$ alkyl, $(C=O)-N(R^6)(R^7)-C_{3-14}$ alkenyl, $(C=O)-N(R^6)(R^7)-C_{3-14}$ alkynyl, $N(R^6)(R^7)-(C=O)-C_{3-14}$ alkyl, $N(R^6)(R^7)-(C=O)-C_{3-14}$ alkenyl, $N(R^6)(R^7)-(C=O)-C_{3-14}$ alkynyl and $N(R^6)(R^7)-(C=O)-C_{3-14}$ alkenyl,

when ~~C~~ is phenyl or HET then ~~B~~ is selected from the group consisting of: C₁-6alkyl, C₁-5alkoxy, -(C=O)-C₁-5alkyl, -(C=O)-O-C₁-4alkyl, -(C=O)-N(R⁶)(R⁷)-C₁-4alkyl, C₁-3alkyl



, phenyl and HET, and

when ~~C~~ is C₁-galkyl, C₁-galkoxy, -(C=O)-C₁-6alkyl or -CHOH-C₁-6alkyl then ~~B~~ is phenyl; and

R⁶ and R⁷ are independently selected from the group consisting of: hydrogen, C₁-9alkyl and -(CH₂)_p-phenyl, wherein p is 1 to 5 and phenyl is optionally substituted with 1-3 substituents independently selected from the group consisting of: C₁-3alkyl and C₁-3alkoxy, each optionally substituted with 1-3 halo groups.

2. (canceled)

3. (original) The compound according to Claim 1 wherein n is 2.

4. (original) The compound according to Claim 1 wherein n is 3.

5. (original) The compound according to Claim 3 wherein each R¹ and R² is independently selected from the group consisting of: hydrogen, -CO₂H, hydroxy, halo, C₁-3alkyl and phenyl.


6 to 10. (canceled)

11. (original) The compound according to Claim 1 wherein R³ is hydrogen or methyl.


12. (original) The compound according to Claim 1 wherein each R⁴ is independently selected from the group consisting of: halo, hydroxy, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, phenyl, benzyloxy and cyclopropyloxy.

13 to 17. (canceled)

18. (original) The compound according to Claim 1 wherein **B-C** is




or



19. (original) The compound according to Claim 1 wherein Ar is phenyl and the group **-B-C** is attached to the phenyl ring at the 3- or 4-position.

20. (currently amended) A compound of Formula II



II

or a pharmaceutically acceptable salt or hydrate thereof, wherein

the group **-B-C** is attached to the phenyl ring at the 3- or 4-position;

n is 2, 3 or 4;

each R¹ and R² is independently selected from the group consisting of: hydrogen, -CO₂H, hydroxy, halo, C₁-3alkyl and phenyl, said C₁-3alkyl and phenyl optionally substituted with 1-3 halo group;

A is selected from the group consisting of: ~~1H tetrazol-5-yl, PO₂H₂, PO₃H₂, -CO₂H and PO(R⁵)OH, wherein R⁵ is selected from the group consisting of: C₁-4alkyl, hydroxyC₁-4alkyl, C(O)C₁-2alkoxy and benzyl, wherein both the methyl and phenyl portions of said benzyl are optionally substituted with 1-3 halo or hydroxyl groups;~~

R³ is hydrogen or methyl;

each R⁴ is independently selected from the group consisting of: halo, hydroxy, C₁-3alkyl, C₁-3alkoxy, C₁-3alkylthio, phenyl, benzyloxy and cyclopropyloxy; and


B-C is selected from the group consisting of:

- (1) ~~B is C₈-10alkyl and C is not present.~~
- (2) ~~B is C₄-11alkoxy and C is not present.~~
- (3) ~~B is phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, C₁-4alkyl and C₁-4alkoxy, and C is selected from the group consisting of: hydrogen, phenyl, C₁-8alkyl, C₁-8alkoxy, (C=O)C₁-6alkyl and CHOHC₁-6alkyl, said C₁-8alkyl, C₁-8alkoxy, (C=O)C₁-6alkyl and CHOHC₁-6alkyl optionally substituted with phenyl;~~


(4) ~~B is $\text{CHOH C}_6\text{-10alkyl}$, $\text{C}_6\text{-10alkylthio}$, $\text{CH}_2\text{-C}_5\text{-9alkoxy}$, $(\text{C=O})\text{C}_6\text{-10alkyl}$, $(\text{C=O})\text{O C}_5\text{-9alkyl}$, $(\text{C=O})\text{N}(\text{R}^6)(\text{R}^7)\text{-C}_5\text{-9alkyl}$ or $\text{N}(\text{R}^6)(\text{R}^7)(\text{C=O})\text{C}_5\text{-9alkyl}$, and C is not present.~~

(5) ~~B is $\text{C}_1\text{-6alkyl}$ or $\text{C}_1\text{-5alkoxy}$ and C is phenyl.~~


(6) ~~B-C is~~



or





21. (currently amended) A compound selected from the group consisting of:




O I P E I A P E
SEP 04 2007
PATENT & TRADEMARK OFFICE


Serial No.: 10/500,811
Case No.: 21020P
Page 8










Serial No.: 10/500,811
Case No.: 21020P
Page 11









Serial No.: 10/500,811
Case No.: 21020P
Page 14




Serial No.: 10/500,811
Case No.: 21020P
Page 15







Serial No.: 10/500,811
Case No.: 21020P
Page 17




Serial No.: 10/500,811
Case No.: 21020P
Page 18




Serial No.: 10/500,811
Case No.: 21020P
Page 19




Serial No.: 10/500,811
Case No.: 21020P
Page 20




Serial No.: 10/500,811
Case No.: 21020P
Page 21




Serial No.: 10/500,811
Case No.: 21020P
Page 22





Serial No.: 10/500,811
Case No.: 21020P
Page 23





Serial No.: 10/500,811
Case No.: 21020P
Page 24

















or a pharmaceutically acceptable salt of any of the foregoing compounds.

22. (withdrawn) A method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound in accordance with Claim 1 in an amount that is effective for treating said immunoregulatory abnormality.

23 to 33. (canceled)

34. (withdrawn) A method of suppressing the immune system in a mammalian patient in need of immunosuppression comprising administering to said patient an immunosuppressing effective amount of a compound of Claim 1.

35. (canceled)